74 related articles for article (PubMed ID: 19760762)
1. ASC/SIL ratio for cytotechnologists: A survey of its utility in clinical practice.
Renshaw AA; Auger M; Birdsong G; Cibas ES; Henry M; Hughes JH; Moriarty A; Tench W; Wilbur DC; Elsheikh TM
Diagn Cytopathol; 2010 Mar; 38(3):180-3. PubMed ID: 19760762
[TBL] [Abstract][Full Text] [Related]
2. ASC/SIL Ratio for Cytotechnologists: A surrogate marker of screening sensitivity.
Renshaw AA; Deschênes M; Auger M
Am J Clin Pathol; 2009 Jun; 131(6):776-81. PubMed ID: 19461082
[TBL] [Abstract][Full Text] [Related]
3. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology.
Davey DD; Neal MH; Wilbur DC; Colgan TJ; Styer PE; Mody DR
Arch Pathol Lab Med; 2004 Nov; 128(11):1224-9. PubMed ID: 15504056
[TBL] [Abstract][Full Text] [Related]
4. Controls in quality assessment in gynecologic cytology: A rational approach to workload limits for the ThinPrep imaging system.
Renshaw AA; Elsheikh TM
Diagn Cytopathol; 2010 Oct; 38(10):772-5. PubMed ID: 20091901
[TBL] [Abstract][Full Text] [Related]
5. Applicability of the Bethesda System 2001 to a public health setting.
Prandi S; Beccati D; De Aloysio G; Fulgenzi P; Gabrielli M; Ghirardini C; Rivasi F; Saragoni L; de Bianchi PS; Bucchi L
Cancer; 2006 Oct; 108(5):271-6. PubMed ID: 16948127
[TBL] [Abstract][Full Text] [Related]
6. Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica.
Sherman ME; Schiffman M; Herrero R; Kelly D; Bratti C; Mango LJ; Alfaro M; Hutchinson ML; Mena F; Hildesheim A; Morales J; Greenberg MD; Balmaceda I; Lorincz AT
Cancer; 1998 Oct; 84(5):273-80. PubMed ID: 9801201
[TBL] [Abstract][Full Text] [Related]
7. HPV detection rate in discordant Pap tests between cytotechnologists and pathologists.
Chhieng DC; Bakdounes K; Connolly M; Gallaspy S; Roberson J; Eltoum I
Diagn Cytopathol; 2009 May; 37(5):320-3. PubMed ID: 19191288
[TBL] [Abstract][Full Text] [Related]
8. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme.
Coleman D; Day N; Douglas G; Farmery E; Lynge E; Philip J; Segnan N
Eur J Cancer; 1993; 29A Suppl 4():S1-38. PubMed ID: 8274301
[No Abstract] [Full Text] [Related]
9. Quality control in cytopathology applied to screening for cervical carcinoma.
Marsan C
Pol J Pathol; 1995; 46(4):245-8. PubMed ID: 8713292
[TBL] [Abstract][Full Text] [Related]
10. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
[TBL] [Abstract][Full Text] [Related]
11. Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey.
Confortini M; Di Bonito L; Carozzi F; Ghiringhello B; Montanari G; Parisio F; Prandi S;
Cytopathology; 2006 Dec; 17(6):353-60. PubMed ID: 17168918
[TBL] [Abstract][Full Text] [Related]
12. Trends in Cervical Cytology Screening and Reporting Practices: Results From the College of American Pathologists 2011 PAP Education Supplemental Questionnaire.
Crothers BA; Darragh TM; Tambouret RH; Nayar R; Barkan GA; Zhao C; Booth CN; Padmanabhan V; Tabatabai ZL; Souers RJ; Thomas N; Wilbur DC; Moriarty AT
Arch Pathol Lab Med; 2016 Jan; 140(1):13-21. PubMed ID: 26046490
[TBL] [Abstract][Full Text] [Related]
13. Increasing cytotechnologist workload above 100 slides per day using the ThinPrep imaging system leads to significant reductions in screening accuracy.
Elsheikh TM; Kirkpatrick JL; Cooper MK; Johnson ML; Hawkins AP; Renshaw AA
Cancer Cytopathol; 2010 Apr; 118(2):75-82. PubMed ID: 20151428
[TBL] [Abstract][Full Text] [Related]
14. Liquid-based cervical cytology.
Klinkhamer PJ; Meerding WJ; Rosier PF; Hanselaar AG
Cancer; 2003 Oct; 99(5):263-71. PubMed ID: 14579292
[TBL] [Abstract][Full Text] [Related]
15. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor.
Zuna RE; Moore W; Dunn ST
Mod Pathol; 2001 Mar; 14(3):147-51. PubMed ID: 11266518
[TBL] [Abstract][Full Text] [Related]
16. Results of the implementation of liquid-based cytology-SurePath in the Ontario screening program.
Colgan TJ; McLachlin CM; Cotterchio M; Howlett R; Seidenfeld AM; Mai VM
Cancer; 2004 Dec; 102(6):362-7. PubMed ID: 15481083
[TBL] [Abstract][Full Text] [Related]
17. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories.
Vassilakos P; Saurel J; Rondez R
Acta Cytol; 1999; 43(1):65-8. PubMed ID: 9987452
[TBL] [Abstract][Full Text] [Related]
18. Predicting screening sensitivity from workload in gynecologic cytology: a review.
Renshaw AA; Elsheikh TM
Diagn Cytopathol; 2011 Nov; 39(11):832-6. PubMed ID: 21994194
[TBL] [Abstract][Full Text] [Related]
19. ASC:SIL ratio following implementation of the 2001 Bethesda System.
Quddus MR; Sung CJ; Eklund CM; Reilly ME; Steinhoff MM
Diagn Cytopathol; 2004 Apr; 30(4):240-2. PubMed ID: 15048957
[TBL] [Abstract][Full Text] [Related]
20. The ASC/SIL ratio for cytopathologists as a quality control measure: a follow-up study.
Nascimento AF; Cibas ES
Am J Clin Pathol; 2007 Oct; 128(4):653-6. PubMed ID: 17875518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
